微光股份(002801.SZ):子公司微光技術未競得浙江馬爾51%股權
格隆匯12月29日丨微光股份(002801.SZ)公佈,浙江馬爾51%股權項目於2021年12月29日競拍結束,參與競拍的為公司全資子公司微光技術和浙江馬爾其他股東,起拍價為人民幣9435萬元,加價幅度為人民幣50萬元或50萬元的整數倍,公司綜合考慮公開披露的信息及盡職調查的情況,決定加價500萬元,競拍價為人民幣9935萬元,因浙江馬爾其他股東行使優先購買權,微光技術最終未能競得浙江馬爾51%股權。
公司全資子公司微光技術未競得浙江馬爾51%股權,不會對公司經營業績造成影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.